In A New Study RotarixTM Offers 96% Protection Against Severe Rotavirus Gastroenteritis And Prevents 100% Of Rotavirus-associated Hospitalisations

Editorial Office

In A New Study RotarixTM Offers 96% Protection Against Severe Rotavirus Gastroenteritis And Prevents 100% Of Rotavirus-associated Hospitalisations

Editorial Office

Abstract

Data from a recent study announced at ESPID (European Society for Paediatric Infectious Diseases) shows that ROTARIXTM, the first oral rotavirus vaccine available to children in Europe, protects against 96% of severe rotavirus gastroenteritis (RVGE) cases and prevents 100% of hospitalisations due to rotavirus-induced gastroenteritis in a European setting.

Issue

Vol 12 No 1 (2008)

Section

Press releases

By submitting manuscripts to PNT, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in PNT for educational and research purposes without obtaining permission.